{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:48:40Z","timestamp":1789771720875,"version":"4.0.1"},"reference-count":21,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background<\/jats:bold>\n                    : Adjuvant therapy with anti\u2010PD\u20101 monotherapy in melanoma is well established. However, a perioperative approach starting immunotherapy before surgery appears mechanistically more reasonable and emerging research results suggest a clinical benefit. This study aims to provide a comprehensive overview of the current use of perioperative anti\u2010PD\u20101 monotherapy in Germany.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Patients and methods<\/jats:bold>\n                    : Patients with stage\u00a0III melanoma who received perioperative anti\u2010PD\u20101 monotherapy from April 2019 to March 2025 were included. Data from eight German skin cancer centers were retrospective collected including histological and radiological assessments.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    : We identified 75 melanoma patients with perioperative anti\u2010PD\u20101 monotherapy. Surgery was conducted in 75% of patients after a median of 11\u00a0weeks after therapy initiation. Pathological assessment revealed a major pathological response (MPR) in 46.5% of cases, a partial pathological response in 23.2%, and no pathological response in 30.4%. A moderate to strong correlation between radiological and pathological responses was identified. During a median follow up period of 11.6\u00a0months, melanoma recurrence was observed in 16 patients (21%). The longest recurrence\u2010free survival was seen in the MPR group.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions<\/jats:bold>\n                    : Perioperative anti\u2010PD\u20101 monotherapy has been implemented in routine clinical practice in German skin cancer centers. The observed outcomes are comparable to data reported from prospective studies.\n                  <\/jats:p>","DOI":"10.1111\/ddg.70355","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:07:52Z","timestamp":1782918472000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Perioperative PD\u20101\u2010inhibition in melanoma patients \u2013 a retrospective analysis from eight German skin cancer centers"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1798-1796","authenticated-orcid":false,"given":"Nina","family":"Flatt","sequence":"first","affiliation":[{"name":"Department of Dermatology, Johannes Wesling Medical Center Ruhr University Bochum, Campus Minden  Minden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Kochanek","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Johannes Wesling Medical Center Ruhr University Bochum, Campus Minden  Minden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6643-7286","authenticated-orcid":false,"given":"Yenny","family":"Angela","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Johannes Wesling Medical Center Ruhr University Bochum, Campus Minden  Minden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C","family":"Hassel","sequence":"additional","affiliation":[{"name":"Heidelberg University, Medical Faculty Heidelberg, Department of Dermatology and National Center for Tumor Diseases (NCT) NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg  Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6185-4945","authenticated-orcid":false,"given":"Andrea","family":"Forschner","sequence":"additional","affiliation":[{"name":"Department of Dermatology Eberhard Karls University of T\u00fcbingen  T\u00fcbingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7090-9584","authenticated-orcid":false,"given":"Christoffer","family":"Gebhardt","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Skin Cancer Center University Medical Center Hamburg\u2010Eppendorf, Hamburg, Germany; Fleur Hiege Center for Skin Cancer Research  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Mengoni","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Allergology and Venereology University Hospital Schleswig\u2010Holstein  L\u00fcbeck Germany"},{"name":"Department of Dermatology University Hospital Magdeburg  Magdeburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai\u2010Martin","family":"Thoms","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Center G\u00f6ttingen, Georg\u2010August\u2010University  G\u00f6ttingen Germany"},{"name":"Department of Dermatology Elbe Klinikum Buxtehude  Buxtehude Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Heppt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Deutsches Zentrum Immuntherapie (DZI) CCC Erlangen\u2010EMN, Bavarian Cancer Research Center (BZKF), Uniklinikum Erlangen, Friedrich\u2010Alexander\u2010Universit\u00e4t Erlangen\u2010N\u00fcrnberg (FAU)  Erlangen Germany"},{"name":"Dermpath M\u00fcnchen, Laboratory for Dermatopathology Oral Pathology and Molecular Pathology  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2073-3909","authenticated-orcid":false,"given":"Julian","family":"K\u00f6tt","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Skin Cancer Center University Medical Center Hamburg\u2010Eppendorf, Hamburg, Germany; Fleur Hiege Center for Skin Cancer Research  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Schulz","sequence":"additional","affiliation":[{"name":"Heidelberg University, Medical Faculty Heidelberg, Department of Dermatology and National Center for Tumor Diseases (NCT) NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg  Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Flatz","sequence":"additional","affiliation":[{"name":"Department of Dermatology Eberhard Karls University of T\u00fcbingen  T\u00fcbingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"T\u00fcting","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Magdeburg  Magdeburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike","family":"Alter","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Johannes Wesling Medical Center Ruhr University Bochum, Campus Minden  Minden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Schaper\u2010Gerhardt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Johannes Wesling Medical Center Ruhr University Bochum, Campus Minden  Minden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Johannes Wesling Medical Center Ruhr University Bochum, Campus Minden  Minden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"1","key":"e_1_2_6_2_1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaad.2024.09.035","article-title":"Global trends in melanoma burden: A comprehensive analysis from the Global Burden of Disease Study, 1990\u20102021","volume":"92","author":"Sun Y","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"e_1_2_6_3_1","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant\u2013adjuvant or adjuvant\u2010only pembrolizumab in advanced melanoma","volume":"388","author":"Patel S P","year":"2023","journal-title":"New Engl J Med"},{"issue":"18","key":"e_1_2_6_4_1","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank CU","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"e_1_2_6_5_1","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized response\u2010directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high\u2010risk stage III melanoma: The PRADO trial","volume":"28","author":"Reijers ILM","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"e_1_2_6_6_1","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/s41591-023-02336-1","article-title":"Neoadjuvant immunotherapy for melanoma is now ready for clinical practice","volume":"29","author":"Garbe C","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"e_1_2_6_7_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1470-2045(24)00627-2","article-title":"Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey","volume":"26","author":"Hauschild A","year":"2025","journal-title":"Lancet Oncol"},{"issue":"1","key":"e_1_2_6_8_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow\u2010up","volume":"36","author":"Amaral T","year":"2025","journal-title":"Ann Oncol"},{"issue":"8","key":"e_1_2_6_9_1","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","article-title":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","volume":"29","author":"Tetzlaff MT","year":"2018","journal-title":"Ann Oncol"},{"key":"e_1_2_6_10_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115485","article-title":"Neoadjuvant immunotherapy for patients with resectable stage III\/IV cutaneous melanoma \u2013 A Swedish retrospective real\u2010world study (NEO\u2010MEL)","volume":"224","author":"Nelson A","year":"2025","journal-title":"Euro J Cancer"},{"key":"e_1_2_6_11_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.042","article-title":"LBA48 Pathologic response and exploratory analyses of neoadjuvant\u2010adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb\u2010IV melanoma from SWOG S1801","volume":"34","author":"Patel S","year":"2023","journal-title":"Ann Oncol"},{"key":"e_1_2_6_12_1","doi-asserted-by":"crossref","first-page":"0009","DOI":"10.2340\/actadv.v106.adv-2025-0009","article-title":"Perioperative pembrolizumab in locally advanced melanoma: A real\u2010world single\u2010centre retrospective study","volume":"106","author":"Goller S","year":"2026","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"e_1_2_6_13_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011483","article-title":"FDG\u2010PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma","volume":"13","author":"Zhou L","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"12","key":"e_1_2_6_14_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e32624","article-title":"Immune mechanisms and predictive biomarkers related to neoadjuvant immunotherapy response in stage III melanoma","volume":"10","author":"Figueiredo AB","year":"2024","journal-title":"Heliyon"},{"key":"e_1_2_6_15_1","doi-asserted-by":"crossref","first-page":"S946","DOI":"10.1016\/j.annonc.2025.08.2229","article-title":"1601O 3\u2010year survival with neoadjuvant\u2010adjuvant pembrolizumab from SWOG S1801","volume":"36","author":"Patel SP","year":"2025","journal-title":"Ann Oncol"},{"issue":"5","key":"e_1_2_6_16_1","first-page":"600","article-title":"Neoadjuvant treatment with immune checkpoint inhibitors in patients with melanoma: A real\u2010life retrospective study","volume":"23","author":"Tomsitz D","year":"2025","journal-title":"J Deutsch Dermatol Ges"},{"key":"e_1_2_6_17_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcskn.2023.100003","article-title":"Neoadjuvant ipilimumab plus nivolumab in locally advanced melanoma: A real\u2010world single\u2010centre retrospective study","volume":"1","author":"Schummer P","year":"2023","journal-title":"EJC Skin Cancer"},{"issue":"3","key":"e_1_2_6_18_1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/bjd.18739","article-title":"Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease","volume":"183","author":"Weber J","year":"2020","journal-title":"Br J Dermatol"},{"issue":"5","key":"e_1_2_6_19_1","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221952","article-title":"IFN\u2010\u03b3 signature enables selection of neoadjuvant treatment in patients with stage III melanoma","volume":"220","author":"Reijers ILM","year":"2023","journal-title":"J Exp Med"},{"key":"e_1_2_6_20_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115257","article-title":"Neoadjuvant or perioperative immunotherapy for resectable melanoma: The need for biomarkers","volume":"217","author":"Ellebaek E","year":"2025","journal-title":"Euro J Cancer"},{"issue":"2","key":"e_1_2_6_21_1","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","article-title":"Survival and biomarker analyses from the OpACIN\u2010neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma","volume":"27","author":"Rozeman EA","year":"2021","journal-title":"Nat Med"},{"issue":"2","key":"e_1_2_6_22_1","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41577-025-01222-w","article-title":"Lessons from neoadjuvant immunotherapy in melanoma: Understanding antitumour immunity and tumour escape","volume":"26","author":"Fallarino F","year":"2026","journal-title":"Nat Rev Immunol"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.70355","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ddg.70355","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.70355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:07:55Z","timestamp":1782918475000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.70355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":21,"alternative-id":["10.1111\/ddg.70355"],"URL":"https:\/\/doi.org\/10.1111\/ddg.70355","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"2026-01-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ddg.70355"}}